Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 3Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 1127Neoplasms 982Carcinoma, Non-Small-Cell Lung 900Prostatic Neoplasms 594Neoplasm Metastasis 528Leukemia, Myeloid, Acute 513Colorectal Neoplasms 491Lung Neoplasms 487Melanoma 485Multiple Myeloma 477Pancreatic Neoplasms 385Lymphoma 369Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 346Leukemia 339Leukemia, Lymphocytic, Chronic, B-Cell 321Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 273Carcinoma, Hepatocellular 261Glioblastoma 249Lymphoma, Large B-Cell, Diffuse 244Myelodysplastic Syndromes 242Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

Sodium Chloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Platinum Resistant Ovarian Cancer × Clear all
NCT02641639 2025-03-24

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Mateon Therapeutics

Phase 2/3 Terminated
70 enrolled 16 charts
Gynecologic

Platinum Resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡